genedrive plc

LSE GDR.L

genedrive plc Capital Expenditure for the year ending June 30, 2024: USD -36.71 K

genedrive plc Capital Expenditure is USD -36.71 K for the year ending June 30, 2024, a 44.39% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • genedrive plc Capital Expenditure for the year ending June 30, 2023 was USD -66.00 K, a 12.56% change year over year.
  • genedrive plc Capital Expenditure for the year ending June 30, 2022 was USD -75.49 K, a 47.51% change year over year.
  • genedrive plc Capital Expenditure for the year ending June 30, 2021 was USD -143.81 K, a -189.96% change year over year.
  • genedrive plc Capital Expenditure for the year ending June 30, 2020 was USD -49.60 K, a 59.72% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
LSE: GDR.L

genedrive plc

CEO Dr. Gino Miele Ph.D.
IPO Date April 4, 2007
Location United Kingdom
Headquarters The CTF Building
Employees 43
Sector Health Care
Industries
Description

genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.

Similar companies

HEMO.L

Hemogenyx Pharmaceuticals Plc

USD 4.80

0.73%

SNG.L

Synairgen plc

USD 0.03

-2.14%

NCYT.L

Novacyt S.A.

USD 0.68

-1.49%

AVCT.L

Avacta Group Plc

USD 0.62

-2.80%

StockViz Staff

January 15, 2025

Any question? Send us an email